Merus (MRUS)
(Delayed Data from NSDQ)
$45.04 USD
+0.11 (0.24%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $45.02 -0.02 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
MRUS 45.04 +0.11(0.24%)
Will MRUS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MRUS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRUS
Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?
Will Merus N.V. (MRUS) Report Negative Q1 Earnings? What You Should Know
MRUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Prothena (PRTA) Surges 12.3%: Is This an Indication of Further Gains?
Other News for MRUS
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
Analysts Have Conflicting Sentiments on These Healthcare Companies: ZimVie Inc (ZIMV) and Merus (MRUS)
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Palantir downgraded, CyberArk initiated: Wall Street's top analyst calls